CHALLENGES IN NEW ANTIMICROBIALS DEVELOPMENT
Antimicrobial resistance - AMR is a global health crisis that is quickly reaching epidemic proportions. Each year, millions of people are infected with drug resistant bacteria, and many die as a result.
The overuse and misuse of antibiotics have accelerated the development of AMR, and traditional approaches to treating infections are becoming increasingly ineffective.
MASSIVE FAILURES
​
There has been no novel class of antibiotics since the early 1950’s.
OUR AIM
To find new classes and to develop the product profiles sensibly for integration into country antibiotic guidelines and subsequent use.
WHAT MAKES US DIFFERENT
USING A DISRUPTIVE APPROACH TOWARDS DRUG DISCOVERY
We are the only company in the World using this disruptive technology, the Resonant Recognition Model - RRM, to discover completely novel antimicrobial peptides which are not binding to the target but inhibit the molecular interaction based on electromagnetic frequency and thus resonance.
We are bringing quantum physics into the realm of medicine.
​
OUR FOCUS AREA NOVEL ANTIMICROBIAL PEPTIDES
QBR developed Peptides BL33 and BL34 are able to inhibit production of beta-lactamase proteins in both Gram Negative and Gram Positive bacteria.
​
